Flagship-backed Axcella seeking NASDAQ IPO

With its lead program headed for its first post-IND clinical study, Axcella proposed to raise up to $86.3 million in an IPO on NASDAQ.

Axcella Health Inc. (Cambridge, Mass.) is developing a pipeline of

Read the full 331 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE